Nitric BioTherapeutics, Inc   Report issue

Contributed to NME For profit Phase 2
Founded: Bristol PA United States (2005)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2005
NCT00823095
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (7)

Key: Nitric BioTherapeutics, Inc (6) Acquired (1)

aciclovir (zovirax) (1 trial)

nitric oxide (inomax) (6 trials)

nitrogen (1 trial)

nitrous oxide (1 trial)

oxygen (1 trial)

terbinafine (lamisil) (2 trials)

water (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leg Ulcer (Phase 2)

Onychomycosis (Phase 2)

Pressure Ulcer (Phase 2)

Skin Ulcer (Phase 2)

Staphylococcal Infections (Phase 2)

Tinea (Phase 2)

Tinea Pedis (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 7